To identify and clarify definitions and methods of measuring cancer-related cognitive impairment among prostate cancer patients treated with androgen deprivation therapy (ADT) and to assess the incidence and prevalence of cognitive impairment. A systematic review of Medline, EMBASE, PubMed, PsycINFO and CINAHL up to December 2015 was undertaken to identify English-language reviews. A total of 28 reviews were identified describing 20 primary studies. There were no studies of incidence. Reported prevalence rates varied between 10% and 69%. Cognitive domains impaired by ADT included: verbal memory, visuospatial ability and executive functions. Cognitive impairment was infrequently defined and four definitions were reported. A variety of measures and methods were used to assess cognitive function including neuropsychological tests, self-report measures and clinical assessments. The finding that, often, one measure was used to assess more than one aspect of cognition is likely to have contributed to imprecise estimates. There is a need to agree a definition of cognitive impairment in the clinical epidemiology of cancer and to standardise the selection of measures in order to aid accurate assessment and fair comparisons across studies regarding the prevalence of cognitive impairment among prostate cancer patients.
| INTRODUCTION
Cognitive impairment among cancer patients may be due to psychosocial factors related to diagnosis or a shared aetiological pathway with tumour growth, e.g. inflammatory response of the immune system (Lange et al., 2014; Myers, 2009) . Treatment-related factors among non-central nervous system tumours beyond chemotherapy may also be implicated. Increasing research attention is being directed towards the side effects of androgen deprivation therapy (ADT) among prostate cancer patients beyond urinary and sexual dysfunction. Increasingly, cognitive impairment is being observed among prostate cancer patients as ADT restricts the production of androgens in order to inhibit tumour growth while potentially having a detrimental effect on cognition (Green et al., 2002) . Cancer-related cognitive impairment has a significant impact on the ability of patients to make informed choices about their treatment (Nelson, Nandy, & Roth, 2007 ) and on activities of daily living and overall quality of life (Wu et al., 2013) . There is a lack of clarity about the clinical epidemiology of cognitive impairment among prostate cancer patients. A brief scoping review was conducted in order to inform our intervention research and development work designed to reduce cognitive impairment in cancer patients (Treanor et al., in preparation) and a number of relevant published reviews were identified. This paper, therefore, identifies and synthesises studies regarding the incidence, prevalence, definition and measurement of cognitive impairment among prostate cancer patients by conducting a review of reviews.
| METHODS

| Search
This review was guided by the Centre for Review and Dissemination's handbook for systematic reviews (Centre for Reviews and Dissemination 2009). A search of MEDLINE, EMBASE, PsycINFO, CINAHL and Social Sciences Citation Index was undertaken in December 2015. The search was restricted to reviews published after 1980 as research directed towards cancer-related cognitive impairment began to appear in the literature at this time. We combined terms describing prostate cancer, cognitive impairment and reviews (see Figure 1 ). Identified papers were exported to Refworks where duplicate papers were removed. Two authors (C.T. and J.L.) independently reviewed each title, abstract and full paper. Discussions were held to identify any discrepancies in studies for inclusion and a consensus was reached. A third author (M.D.) was available if a consensus could not be reached regarding paper inclusion.
| Inclusion and exclusion criteria
Reviews which addressed at least one aspect of the epidemiology of cognitive impairment including incidence, prevalence, definition and measurement of cognitive impairment among prostate cancer patients were included as were reviews of studies of patients who had completed or were currently receiving ADT in isolation or in combination with other treatments. The scoping review indicated that many published reviews did not report their review methods so it was not possible to judge whether they were conducted systematically.
So, papers which were described and/or indexed as a review were included. Reviews of prostate cancer patients in palliative care and studies that addressed cognitive impairment across multiple cancer sites unless separate data were available for prostate cancer patients were excluded.
A total of 143 papers remained for title screening after duplicates had been removed. Forty-seven papers remained following abstract screen and 25 full papers were reviewed for inclusion in the review.
Sixteen reviews met the inclusion criteria and were included in the review. A further 12 studies were identified from the citation lists of included studies. In total, 28 papers are included in the review. 
| RESULTS
| Review characteristics
Twenty-eight reviews (Ahles & Saykin, 2007; Artherholt & Fann, 2012; Beauchet, 2006; Biegler, Chaoul, & Cohen, 2009; Chen & Petrylak, 2004; Chism & Kunkel, 2009; Droz et al., 2010; Falci, Morello, & Droz, 2009; Green, Pakenham, & Gardiner, 2005; Grossmann & Zajac, 2011; Gruca, Bacher, & Tunn, 2012; Harrington et al., 2010; Holzbeierlein, 2006; Isbarn et al., 2009; Jamadar, Winters, & Maki, 2012; Janelsins et al., 2011; Mitsiades et al., 2008; Mohile et al., 2009; Mottet et al., 2006; Nelson et al., 2008; Scherr & Pitts, 2003; Sharifi, 2005; Tombal, 2009; Trost et al., 2013; Wefel, Kayl, & Meyers, 2004; Wright, Higano, & Lin, 2006; Ziółkowska et al., 2012) described 20 primary studies (Alibhai et al., 2010; Almeida et al., 2004; Beer, Bland, Garzotto, Ryan, & Janowsky, 2004; Beer et al., 2006; Bloomfield, Shilling, Edington, & Jenkins, 2004; Bussiere et al., 2005; Cherrier, Aubin, & Higano, 2009; Cherrier, Rose, & Higano, 2003; DiBlasio et al., 2008; Green et al., 2002 9. (prevalen* or inciden* or measure* or definit*).mp.
10. 5 and 8 and 9
11. limit 10 to yr = "1980 -Current" 12. limit 11 to (English language and "review articles") | 3 of 18 TREANOR ET Al. Salminen et al., 2003 Salminen et al., , 2004 Salminen et al., , 2005 Shahinian et al., 2006; Verhagen, Wissenburg, Wildhagen, & Mickisch, 2008) were included in the review, see Table 1 . The reviews were conducted by institutions in USA (n = 19), Europe (n = 8) and Canada (n = 1). Twenty-two reviews focussed on the uses and side effects of ADT, one review focussed exclusively on ADTrelated cognitive impairment; the remaining reviews focussed generally on cancer-or treatment-related cognitive impairment (n = 7) and on general cancer-related side effects (n = 4). Two reviews focussed on cancer within elderly populations with consideration given to treatment which may augment risk of cognitive impairment; other reviews considered testosterone (n = 1) and diethylstilboestrol (n = 1) in relation to cognitive function among individuals with cancer. The reviews reported infrequently the prevalence, definition or measurement of cancerrelated cognitive impairment among prostate cancer patients, thus this information was extracted from the cited primary studies. None of the reviews reported on the incidence of cancer-related cognitive impairment among prostate cancer patients.
| Definition
None of the reviews defined cognitive impairment; however, one review calculated Reliable Change Index (RCI) data from the primary studies (Jamadar et al., 2012) . Many of the primary studies did not define cognitive impairment in any way. Four operational definitions of cognitive impairment were reported across the studies. A RCI which takes into account practice effects of performance on neuropsychological test measures was used in three studies (Cherrier et al., 2003; Green et al., 2002; Jenkins et al., 2005) . Two further studies defined impairment in terms of deviation of scores on neuropsychological tests from population or non-cancer control norms, i.e. 1.5 standard deviations (Salminen et al., 2004) or in terms of 1, 2 or 3 deterioration points corresponding to 1.5, 2 or 3 standard deviations (Mohile et al., 2010) . Diagnostic criteria were used to define cognitive impairment in two studies: one study used International Classification of Diseases version 9 (ICD-9) codes for cognitive disorders (Shahinian et al., 2006) and a further study utilised criteria from the Diagnostic Statistical Manual of Mental Disorders version IV (DSM-IV) (DiBlasio et al., 2008) . A further study utilised categorical cut-offs on the established High Sensitivity Cognitive Screen (HSCS) measure to define levels of impairment including normal functioning, mild, moderate or severe impairment (Joly et al., 2006) .
| Measurement
Aspects of cognition measured across the studies are reported in (Salminen et al., 2003 (Salminen et al., , 2004 (Salminen et al., , 2005 . Some neuropsychological test measures were used to assess as many as three different cognitive domains, e.g. the Weschler Adult Intelligence Scale (WAIS) digit symbol was used to assess visuospatial ability, spatial memory and attention (see Table 3 ).
| Prevalence
Similar proportions of prostate cancer patients were found to have cognitive decline on neuropsychological test measures across four studies.
In one study, 52% of men over the age of 50 years who were due to initiate at least 6-month ADT for prostate cancer scored 1.5 standard deviations below population norms for verbal and visual memory. Moreover, 45% met the criteria for mild cognitive impairment at 6-month follow-up. The authors also calculated a RCI for each test measure. Declines were observed in executive functions among 38% of prostate cancer patients, visuospatial ability among 24%, verbal memory among 19%, verbal fluency among 14% and visual memory among 10% of patients (Mohile et al., 2010) .
Additionally, approximately 50% of men with prostate cancer demonstrated reliable decline on seven of eight neuropsychological tests before initiation of intermittent ADT (IADT) to 9 months of treatment. Declines on specific cognitive domains include spatial ability (69%) during ADT, whereas 15% of men experienced decline 3 months off-ADT (Cherrier et al., 2003) .
One study randomised 82 men with localised prostate cancer (mean age 73.3 years) to active surveillance or hormonal therapy.
Neuropsychological assessments were taken at baseline 1 week prior to ADT initiation and 6 months later. Prevalence of cognitive impairment was operationalised in terms of a RCI. Forty-eight per cent (n = 24) and 14% (n = 7) of men on ADT demonstrated reliable decline since baseline on at least one or two neuropsychological test measures respectively. Declines were commonly experienced in the attention and verbal memory domains. There was an absence of reliable decline among men who were being actively monitored (Green et al., 2002) .
A similar proportion of men with prostate cancer (47%) demonstrated reliable decline on at least one neuropsychological test measure from baseline (preluteinising hormone releasing hormone [LHRH] use) to 3 months of, or completion of, LHRH. This impairment was experienced commonly in visuospatial ability and memory. Compared to men without prostate cancer, men who received LHRH had a significant fourfold increase in odds of cognitive decline on at least one measure (odds ratio [OR] = 4.412; p = .03). At the 9-month assessment point, reliable decline was observed among 34% (n = 11) of men with prostate cancer compared to 28% (n = 5) of men without prostate cancer (OR = 1.37, p = .63). Again, the impairment was predominantly related to visuospatial ability (Jenkins et al., 2005 Review methods were not reported N = 1 study cited (Jenkins et al., 2005) Number of participants • Jenkins et al. (2005) : N = 50 (32 patients with localised prostate cancer treated with 3-5 months of luteinising hormone-releasing hormone (LHRH) agonist prior to radical radiotherapy and 18 men with no prostate cancer) Prevalence
• Forty-seven per cent (n = 15) of prostate cancer patients demonstrated reliable decline on at least one cognitive task compared to 17% (n = 3) of controls from T1 (prior to LHRH commencement) to T2 (3 months later or completion of LHRH but prior to radical radiotherapy) (odds ratio 4.412, p = .033). Most patients (9 of 15) who had a change in performance declined on tasks of spatial memory and ability. At T3 (9 months since baseline assessment) reliable cognitive decline was observed among 11 (34%) prostate cancer patients and five (28%) control participants (odds ratio 1.37, p = .631). Declines were observed predominantly in visuospatial ability Definition
• A Reliable Change Index (RCI) was calculated to capture change in cognition scores over time taking into account practice effects Measurement No further information relating to review methods were reported N = 7 studies cited (Almeida et al., 2004; Cherrier et al., 2003; Green et al., 2002 Green et al., , 2004 Jenkins et al., 2005; Salminen et al., 2003 Salminen et al., , 2004 Number of participants • Green et al. (2002) , N = 82 patients with non-localised prostate cancer randomised to active treatment (including leuprolide, goserelin, or cyproterone acetate) or active monitoring.
• Green et al. (2004) As above in (Green et al., 2002) with an additional follow-up at 12 months post-treatment commencement and an additional age-matched control group without prostate cancer (n = 20).
• Jenkins et al. (2005) reported elsewhere in the table • Cherrier et al. (2003 ) N = 34:19 men with prostate cancer due to initiate intermittent ADT and treated with radiotherapy, brachytherapy and prostatectomy with biochemical relapse after primary therapy treated compared to 15 controls without prostate cancer. Baseline was captured prior to ADT initiation, follow-up at 9 months of treatment and after 3 months of treatment completion.
• Salminen et al. (2003) N = 25 men with locally advanced prostate cancer set to receive neo-adjuvant ADT and 52 controls without prostate cancer matched for age, education, and baseline mini-mental status exam score. Assessments were taken at baseline, 6 months and 12 months after ADT initiation • Salminen et al. (2004) , N =26 patients with prostate cancer due to commence ADT. No control group. Assessments taken prior to baseline, 6 months and 12 months later.
• Almeida et al. (2004) Author's conclusion
Prevalence
• Forty-eight per cent (n = 24) of patients on ADT reliably declined over time from baseline assessment prior to commencement of ADT to follow-up, 6 months later on at least one test measure, no controls demonstrated decline. Fourteen per cent (n = 7) of patients on ADT experienced cognitive decline on two tests. Declines were commonly experienced in attention and memory domains. When exposed to the same stimuli improvments in memory were observed among prostate cancer patients on active ADT up to 12 months post-baseline assessment (Green et al., 2002) • Prevalence of CRCI not reported, although significantly poorer performance in verbal learning and attention tasks among prostate cancer patients compared to community controls were observed at 6-month and 12-month follow-up. Men receiving goserelin recalled significantly less words on the verbal learning test than men receiving leuprorelin at 6 months (p = .008). Men who were receiving active surveillance recalled more words on the verbal learning test at 12 months than men receiving active treatment (p = .014) (Green et al., 2004) • Less than 50% of men with prostate cancer were scored as having reliably declined on seven of eight tests. Sixty-nine per cent of men experienced reliable decline in mental rotation tasks during treatment, recovery was made among the majority of men as 15% only of men experienced decline after 3 months of completing ADT (Cherrier et al., 2003) • No prevalence rates reported, men with prostate cancer experienced significant deficits in verbal and visuomotor performance and sustained attention compared to controls. Compared to baseline scores, improvement among prostate cancer patients in episodic and semantic memory after 12 months of ADT. No impairment over time for cognitive processing among men with prostate cancer from baseline to 12 months (Salminen et al., 2003) • No prevalence rates reported. Deterioration over 12 months in visuomotor speed, recognition time and subtraction time. Improvements in object recall over 12 months (Salminen et al., 2004) • No prevalence rates reported. After discontinuation of ADT CAMCO-G scores and memory improved. ADT did not have an impact on visuospatial abilities (Almeida et al., 2004 ) Definition
• A reliable change index was calculated (Cherrier et al., 2003; Green et al., 2002) .
• Overall cognitive deterioration score was calculated based on norms calculated from healthy controls. One, two and three deterioration score(s) were given if a patient scored 1.5, 2 or 3 standard deviations below norms. A maximum score of 18 was permitted (Salminen et al., 2003) • CRCI not defined (Almeida et al., 2004; Green et al., 2004; Salminen et al., 2004 ) Measurement
• Verbal memory: Wechsler Memory Scale-Revised (WMS-R) verbal sub-test (Green et al., 2002 (Green et al., , 2004 ; proactive interference, story recall (Cherrier et al., 2003) , WAIS similarities (Salminen et al., 2003 (Salminen et al., , 2004 , verbal fluency, picture naming (Salminen et al., 2004) , digit span (Salminen et al., 2003) , WMS word lists, WMS verbal paired associates (Almeida et al., 2004) • Visual memory: WMS-R visual sub-test sub-tests, Auditory Verbal Learning Test (AVLT) (Green et al., 2002 (Green et al., , 2004 , Benton visual memory and visual span (Salminen et al., 2004) , WMS visual reproduction subtest (Almeida et al., 2004) • Delayed recall: Rey-Osterrieth Complex Figure Test (ROCFT) (Green et al., 2002 (Green et al., , 2004 T A B L E 1 (Continued) (Green et al., 2002 (Green et al., , 2004 CogniSpeed software (Salminen et al., 2003 (Salminen et al., , 2004 • Executive function: Stroop test (Cherrier et al., 2003; Green et al., 2002 Green et al., , 2004 and ROCFT copy trial (Green et al., 2002 (Green et al., , 2004 • Visuomotor/Spatial memory: route test (Cherrier et al., 2003) , WAIS digit symbol (Salminen et al., 2003 (Salminen et al., , 2004 and WAIS block design (Almeida et al., 2004; Salminen et al., 2003 Salminen et al., , 2004 • Spatial ability: mental rotation using blocks (Cherrier et al., 2003) • Cognitive processing: CogniSpeed software (Salminen et al., 2003 (Salminen et al., , 2004 • Episodic memory: naming time, immediate, delayed memory and recall, word list recall, Benton Visual Memory Retention Test-visual recognition test and visual memory span (Salminen et al., 2003 (Salminen et al., , 2004 • • Fifty-two per cent of patients scored more than 1.5 standard deviations below population means for verbal and visual memory. Forty-five per cent met the criteria for mild cognitive impairment (i.e. below expected performance on one standardised measure). Reliable decline observed for verbal memory (19%), visual memory (10%), visuospatial ability (24%), executive function (38%) and language (14%). Reliable improvements observed for verbal memory (24%), visual memory (10%), visuospatial ability (48%), executive function (29%) and language (10%) (Mohile et al., 2010) • No reported prevalence, however, association between levels of testosterone and scores on working memory tasks (Alibhai et al., 2010) Definition:
• Impairment was defined as scoring more than 1.5 standard deviations below the age-and education-adjusted population reference mean for that test (Mohile et al., 2010) • A reliable change index was calculated (Mohile et al., 2010) • CRCI not defined (Alibhai et al., 2010 ) Measurement
• Attention: Trail Making Test A & B, WAIS digit span (forward and backward) (Mohile et al., 2010) , WAIS digit span forward, spatial span forward (Alibhai et al., 2010) • Visual memory: Brief Visual Spatial Learning Test (Alibhai et al., 2010; Mohile et al., 2010) • Visuospatial ability: Judgement line of orientation, card rotation (Alibhai et al., 2010) • Language: Controlled Oral Word Association Test (COWAT) (Alibhai et al., 2010; Mohile et al., 2010) Cognition of men with prostate cancer treated with ADT is affected, although more research is needed.
T A B L E 1 (Continued) PubMed and EMBASE were searched post-1999 for peer-reviewed English-language clinical trials, randomised controlled trials and review articles that included at least 10 human male adult subjects N = 3 studies cited (Almeida et al., 2004; Cherrier et al., 2003; Salminen et al., 2004) • Information related to these studies is reported elsewhere in this Review methods were not reported N = 2 studies cited Beauchet, 2006) • Information related to these studies is reported elsewhere in this table
There appears to be an association between ADT and cognitive function, however, more research is needed Chen and Petrylak (2004) , USA To review the effects of ADT and ways to manage or minimise these effects Review methods were not reported N = 2 studies cited (Green et al., 2002; Salminen et al., 2003) • Information related to these studies is reported elsewhere in this Review methods were not reported N = 1 study cited (Shahinian et al., 2006) Number of participants
• N = 101,089. (n = 50,613 men with prostate cancer (ADT use n = 15,748 and non-ADT n = 34,685) and 50,476 men without cancer) Prevalence
• Thirteen point 9% of with prostate cancer receiving ADT; 10.2% of men with prostate cancer not receiving ADT and 7.9% of non-cancer controls between 6 and 60 months post-diagnosis or study entry (p < .001).
• Unadjusted risk ratio of cognitive disorders among men receiving ADT vs. no ADT (RR = 1.44, 95% CI = 1.38-1.50); Adjusted RR = 0.99, 95% CI = 0.94-1.04 (adjustments for ADT use, age at diagnosis or study entry, ethnicity, SEER region, education, income, comorbidity, diagnosis of cognitive disorder, depression or constitutional disorder 12 months prior to study entry, cancer grade and stage, radiotherapy history, prostatectomy, provider visits in 12 months prior to study enrolment) (Green et al., 2002) • Information relating to this study is reported elsewhere in the Review methods were not reported N = 4 studies cited (Cherrier et al., 2003; Green et al., 2002 Green et al., , 2004 Salminen et al., 2003) • Information relating to these studies is reported elsewhere in the Review methods were not reported N = 1 study cited (Shahinian et al., 2006) • Information related to this study is reported elsewhere in the (Green et al., 2002; Jenkins et al., 2005) • Information relating to these studies are reported elsewhere in the Review methods were not reported N = 3 studies cited (Green et al., 2002; Salminen et al., 2004) • Information relating to these studies are reported elsewhere in the table
Authors did not give a conclusion regarding cognitive impairment (Isbarn et al., 2009) , Germany To discuss when ADT is used and its benefits and side effects MEDLINE was searched using the terms: prostate cancer, hormonal therapy, adverse effects, radical prostatectomy and radiotherapy for primary empirical studies and reviews. Two or more independent data extractors N = 2 studies cited (Cherrier et al., 2003; Salminen et al., 2004) • Information relating to these studies are reported elsewhere in the • Neither of these aspects were assessed in the review N = 9 studies cited (Cherrier et al., 2009) • Alibhai et al. (2010) Review methods were not reported N = 4 studies cited (Green et al., 2004; Mohile et al., 2010; Nelson et al., 2008; Salminen et al., 2003) • Information relating to these studies is reported elsewhere in the There is mixed evidence to support whether ADT is associated with cognitive decline among prostate cancer patients Mohile et al. (2009) , USA To review the evidence for complications related to ADT use and how they should be managed Review methods were not reported N = 8 studies cited (Almeida et al., 2004; Cherrier et al., 2003; Green et al., 2002 Green et al., , 2004 Jenkins et al., 2005; Joly et al., 2006; Salminen et al., 2003 Salminen et al., , 2004 • Information related to these studies are reported elsewhere in the table   The relationship  between ADT and  cognition Author's conclusion Nelson et al. (2008) , USA To explore possible mechanisms for the association between hormonal therapy and cognition PubMed and Web of Science were searched using the terms: androgen deprivation therapy and cognition; no further information relating to the review methods were reported N = 9 studies cited (Beer et al., 2006; Bussiere et al., 2005; Salminen et al., 2005) • Information relating to these studies are reported elsewhere in the table (Almeida et al., 2004; Cherrier et al., 2003; Green et al., 2002; Jenkins et al., 2005; Joly et al., 2006; Salminen et al., 2004) Number of participants • Salminen et al. (2005) , N = 23 men newly diagnosed with prostate cancer set to initiate ADT. Cognitive assessments were taken at baseline, 6 and 12 months on ADT.
• Bussiere et al. (2005) , N = 30 [men with prostate cancer receiving ADT (n = 14) and a matched group of men without cancer (n = 16)].
• Beer et al. (2006 ) N = 53 (n = 18 men with prostate cancer who had completed ADT and to initiate estradiol therapy; n = 18 men with prostate cancer presently undergoing ADT and n = 17 men without cancer) Prevalence
• Not reported; however, declines were observed in verbal fluency, visual recognition and visual memory (Salminen et al., 2005) ; Retention and recognition of words was impaired among the prostate cancer group compared to the control group (Bussiere et al., 2005) and; at baseline, men with prostate cancer had poorer immediate and delayed memory recall than men without cancer (Beer et al., 2006 ) Definition
• Not reported (Beer et al., 2006; Bussiere et al., 2005; Salminen et al., 2005 ) Measurement
• Cognitive processing: CogniSpeed (Salminen et al., 2005) • Attention: CogniSpeed (Salminen et al., 2005) • Verbal skills/naming: WAIS similarities and verbal fluency • Visuomotor skills: WAIS digit symbol and WAIS block design (Salminen et al., 2005) • Verbal memory: WAIS digit span forward/backward, WMS word list recall (Salminen et al., 2005) Toronto Word Pool (Bussiere et al., 2005) • Visual memory: WMS visual span forward/backward; Benton Visual Retention Test (Salminen et al., 2005) • LT memory: Delayed Paragraph Recall Test (Beer et al., 2006) • Working memory: Subject Ordered Pointing and Trail Tests (Beer et al., 2006) • Assessed cognition with the Cambridge Examination for Mental Disorders of the Elderly-Cognitive Battery (CAMCO-G) and with tests of verbal memory, visual memory and visuospatial ability ADT appears to be linked to cognitive declines in men with prostate cancer Scherr and Pitts (2003) , USA To uncover some of the non-hormonal non-steroidal effects of diethylstilbestrol Searches were carried out between 1935 and 2003; further information in relation to review methods was not reported N = 1 study cited (Green et al., 2002) • Information relating to this study has been reported elsewhere in the was given to controlled studies N = 3 studies cited (Green et al., 2002; Salminen et al., 2003 Salminen et al., , 2005 • Information relating to these studies is reported elsewhere in the table
Authors did not give a conclusion in relation to cancer-related cognitive impairment Trost (2013) , Belgium To provide on how to monitor and counsel patients and effectively manage side effects based on a review of the literature Review methods were not reported N = 2 studies cited (Holzbeierlein, 2006; Mottet et al., 2006) • Information relating to these studies is reported elsewhere in the table
Authors did not give a conclusion in relation to cancer-related cognitive impairment Trost (2013) , USA To review adverse events associated with ADT as well as treatment options
PubMed was searched; further details methods were not reported N = 5 studies cited (Alibhai et al., 2010; Cherrier et al., 2003 Cherrier et al., , 2009 Salminen et al., 2003 Salminen et al., , 2005 • Information relating to these studies is reported elsewhere in the review
The impact of ADT on cognitive functioning is unclear Wefel et al. (2004) , USA To review the literature regarding cancer-related cognitive impairment
Review methods were not reported N = 2 studies cited (Green et al., 2002; Salminen et al., 2003) • Information relating to these studies is reported elsewhere in the table   There are inconsistent  findings with relation to ADT-related cognitive decline Wright et al. (2006) , USA To review benefits, rationale and trials relating to IAD Review methods were not reported N = 2 studies cited (Almeida et al., 2004; Cherrier et al., 2003) • Information relating to these studies is reported elsewhere in the Review methods were not reported N = 2 studies cited (Holzbeierlein, 2006; Tombal, 2009) • Information relating to these reviews are reported elsewhere in the table
Authors did not give a conclusion a If information was not available in the review; the primary studies were examined.
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A cohort study utilising the Surveillance Epidemiology and End
Results (SEER) programme identified 101 089 men, including men with prostate cancer who were undergoing ADT (n = 15 748) or not undergoing ADT (n = 34 685) and men without cancer (n = 50 476).
There was a significant difference (p < .001) in the proportion of men with cognitive disorders (according to ICD-9 codes) across groups:
13.9% of prostate cancer patients receiving ADT, 10.2% of prostate cancer patients not receiving ADT and 7.9% of men without cancer. 82%; m/s: 18%) and planning (n/m: 95%; m/s: 5%). The differences between groups were not statistically significant (Joly et al., 2006) .
Although many of the studies did not report the proportion of men who experienced cognitive impairment, patterns of impairment were observed in verbal memory (Green et al., 2004) , attention (Green et al., 2002) and of being diagnosed with a clinically important cognitive disorder (Shahinian et al., 2006) among men who received ADT compared to men who did not receive ADT.
The premise of intermittent ADT is that many of the side effects of ADT can be attenuated during the non-treatment, "wash-out" period.
This was supported in two studies (Almeida et al., 2004; Cherrier et al., 2003) , however, men receiving intermittent ADT reported poorer scores on a self-reported cognitive function measure compared to men receiving continuous ADT (Verhagen et al., 2008) .
Compared to men without cancer, poorer test performance was observed among men with prostate cancer receiving ADT in verbal memory (Beer et al., 2006; Green et al., 2004; Salminen et al., 2003) , attention (Green et al., 2004; Salminen et al., 2003) , visuomotor ability (Cherrier et al., 2009; Salminen et al., 2003) , executive functions (general) (Cherrier et al., 2009 ) and processing speed (Beer et al., 2006) . Improvements in cognitive function among men with prostate cancer receiving ADT were reported in a small number of studies.
Improvements in verbal memory (24%), visual memory (10%), visuospatial ability (48%), executive functions (29%) and language (10%) were observed in one study (Mohile et al., 2010) . Using a RCI to determine improvement in cognitive function, 5%-6% of prostate cancer patients receiving treatment improved on one or more test. With regard to
Cognitive domain Measure
individual cognitive domains, 4%-9% of patients improved on verbal ability, 13% improved on visuospatial ability and 4%-7% improved on working memory (Jenkins et al., 2005) . Compared to baseline scores, an improvement among prostate cancer patients in episodic and semantic memory (Salminen et al., 2003) and object recall (Salminen et al., 2004) after 12 months of ADT was observed. When exposed to the same stimuli, improvements in memory were observed among prostate cancer patients on active ADT up to 12 months post-baseline assessment (Green et al., 2004) . Verbal ability improved for a sub-group of prostate cancer patients receiving cyproterone (Green et al., 2002 ). Due to the number of measures used across studies, it is difficult to discern any one measure that should be recommended to assess individual cognitive domains among prostate cancer patients.
| DISCUSSION
There is a need to clarify and agree a definition of cognitive impairment in the clinical epidemiology of cancer and to standardise the selection of measures in order to aid accurate assessment and fair comparisons across studies regarding the prevalence and rate of cognitive impairment among men with prostate cancer. The general pattern of impairment among prostate cancer patients treated with ADT tends to relate to executive functions, visuospatial, verbal memory, verbal fluency and spatial ability. Many of the studies were observational, whereas a few studies were of an experimental design and there was variability in the use of appropriate comparators. Many studies included healthy men without cancer as controls, however, the extent to which this kind of control is appropriate is questionable given that disease-related factors associated with cognitive function cannot be taken into account. Neuroimaging techniques may be used as an additional objective assessment to elucidate further the effects on ADT on cognitive functions (Chao et al., 2013) .
The focus of this review was on cognitive impairment among men with prostate cancer treated with ADT. However, it is instructive to note that improvements in functions were observed and that some studies reported no differences between men with prostate cancer and men without cancer and men not treated with ADT. In the case of verbal memory and visuospatial ability in one study (Mohile et al., 2010) , the number of men who improved was greater than the number of men who declined; as these changes in scores were calculated using a RCI, the rate of improvement is beyond practice effects only.
Further analysis by the study authors suggest that men with average or better than average scores at baseline demonstrated improvements over the course of the study. The remaining studies that reported improvements in cognitive function among prostate cancer patients were unable to discern individual risk factors for the increased risk of development of cognitive impairment.
As noted above, many papers did not clearly operationalise cognitive impairment and it is important that future studies provide clear definitions. In particular, the use of methods such as a RCI which take into account practice effects may provide an indication of clinically relevant cognitive impairment among prostate cancer patients. It may appear unusual that a larger number of reviews than primary studies were identified; this is in part due to the varying focus of the included reviews, with many reviews not focused specifically on ADT-related cognitive impairment.
| Strengths and limitations
An important component of a review of reviews is an appraisal of the methodological quality of each paper using tools such as the Assessment of Multiple Systematic Reviews (AMSTAR) (Shea et al., 2007) . We did not assess methodological quality per se because the reviews did not address specifically our research questions and because along with the primary studies in the reviews, we used the reviews to find and extract data about conceptual aspects and the nature and prevalence of cognitive impairment. This paper presents a synthesis of the only available research on the epidemiology of cognitive impairment among prostate cancer patients.
| CONCLUSION
The variation in use of measures and infrequently reported definitions of impairment has contributed to a wide variation in reported prevalence rates of impairment among prostate cancer patients receiving ADT. Consistent use of measures with a clear operationalised definition of impairment within well-designed and powered studies are needed in the future in order to calculate accurate estimates, identify at-risk patients and design and deliver appropriate and effective preventative and compensatory strategies that address cognitive decline in this already vulnerable group of patients.
